Roth Capital upgraded shares of Cresco Labs (OTCMKTS:CRLBF – Free Report) from a hold rating to a strong-buy rating in a research report sent to investors on Friday, Zacks.com reports. Roth Capital also issued estimates for Cresco Labs’ Q4 2024 earnings at $0.01 EPS and FY2025 earnings at $0.03 EPS.
CRLBF has been the topic of several other research reports. Wedbush upped their target price on Cresco Labs from $2.50 to $3.00 and gave the company an outperform rating in a research report on Thursday, May 16th. Needham & Company LLC reiterated a hold rating on shares of Cresco Labs in a research report on Thursday, May 16th. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of Buy and an average target price of $2.63.
View Our Latest Stock Analysis on CRLBF
Cresco Labs Price Performance
Cresco Labs (OTCMKTS:CRLBF – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.15). Cresco Labs had a negative return on equity of 6.78% and a negative net margin of 20.32%. The business had revenue of $184.36 million for the quarter, compared to analyst estimates of $184.26 million. On average, research analysts expect that Cresco Labs will post -0.03 EPS for the current fiscal year.
Cresco Labs Company Profile
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Further Reading
- Five stocks we like better than Cresco Labs
- Compound Interest and Why It Matters When Investing
- How to Invest in Silver: A Beginner’s Guide
- Upcoming IPO Stock Lockup Period, Explained
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.